Inovio Pharma (INO)
$8.33
0.10 (1.19%)
INO Stock Quote Delayed 30 Minutes
Is Inovio Pharmaceuticals a Good Buy on Coronavirus Potential?
Inovio stock is up on hopes of solving the coronavirus puzzle. But INO stock has plenty of competition in that regard.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
1.75B
PE Ratio
-1.15
EPS
-7.24
Volume (Avg. Vol.)
136,628
Day's Range
$8.25 - $8.59
52-Week Range
$0.32 - $14.75
Dividend & Yield
N/A (N/A)
INO Stock Predictions, Articles, and Inovio Pharma News
Inovio Is Still Hot as the Coronavirus Spreads
INO stock still has some serious upside, thanks to its INO-4800. Inovio's coronavirus vaccine takes the lead and is in preclinical trials.
Inovio Could Be a Bargain Using Probability Analysis
Inovio could be a bargain using probability analysis. INO stock is cheap if there is a greater than 5% chance its COVID-19 vaccine will be successful.
Inovio Rise is Today’s Sign of the Stockocalypse
Inovio has a coronavirus vaccine candidate that has just entered testing, and INO stock speculators are going mad over it.
Can Inovio’s Vaccine Efforts Maintain Growth for INO Stock?
Once an afterthought in the pharmaceutical space, INO stock suddenly looks interesting amid the coronavirus pandemic. However, it could also be a very temporary tailwind.
As the Coronavirus Worsens, INO Stock Gets More Interesting
Gambling on a single vaccine play is always risky. However, INO stock may have substance given that the coronavirus could get a lot worse.
Inovio Stock Is Still Too Volatile Despite Grant Support for Vaccine
Inovio may look promising as a contender in the race to develop a vaccine, but INO stock is still very risky. Here's what to look out for.
INO Stock Is a Purely Speculative COVID-19 Vaccine Play
The timeline to develop the vaccine seems unrealistic. Further, clinical trials will provide credibility to claims.
Don’t Buy Inovio Stock on Hopes for a Vaccine
Coronavirus hysteria on Wall Street is temporary. When it passes, INO stock could turn into a "look out below" situation.
Stock Market Today: Stocks Hit Panic Point, Trigger Trading Halt
Oil prices plunged more than 33% at one point, while stock trading was temporarily halted. Here's what happened in the stock market today.
Race to Respond to Coronavirus Threat a Boon for Inovio Stock
As the world races for a coronavirus vaccine, Inovio remains one of the top “must own” stocks. If it sees success in human trials and can begin delivery of its vaccine this year, I wouldn’t be shocked to see shares of INO closer to $20 a share.
Is Inovio Pharmaceuticals Stock the Cure for Your Portfolio?
Inovio Pharmaceuticals continues to rally on COVID-19 vaccine hopes, but overbought conditions and key challenges still make INO stock a risky proposition.
Don’t Get Sucked Into Vaccine Hype, INO Stock Is Overbought
INO stock isn't worth chasing as vaccine development may not be as rewarding as the market seems to believe it is.
Inovio Pharmaceuticals Rapidly Becoming The Premier Coronavirus Play
Inovio is benefiting from the coronavirus outbreak, but there's plenty of speculation and volatility in this stock too.
Is Inovio Stock a Buy on Coronavirus Cure Potential?
INO stock has screamed higher on the possibility of a coronavirus vaccine but the underlying company isn't the most fiscally stable.
Is Inovio Stock Still a Buy After Its Massive 150% Leap This Year?
Inovio is developing a potential vaccine for the coronavirus. If you can handle the volatility, it may be time to buy INO stock.
Inovio Pharmaceuticals News: INO Stock Rockets 12% on Accelerated Coronavirus Vaccine Timeline
Inovio Pharmaceuticals (INO) news for Wednesday concerning a vaccine for the coronavirus from China has INO stock skyrocketing.
Inovio Has Potential Beyond Its Speculative Coronavirus Vaccine
INO stock has had a nice rally lately, primarily driven by the coronavirus. But this company has other treatments that could move the needle.
Traders Are Treating Inovio Like 2018’s Pot Stock Stars
Inovio is working on a long-shot vaccine against China's coronavirus and traders are treating INO stock like a true star.
Inovio’s Coronavirus Vaccine Makes INO Stock Worth a Bet
Speculators are betting that INO stock and its vaccine are coronavirus killers, but the biotechnology firm may be more than just that.
There Is No Good Play When It Comes to INO Stock
With this in mind, what's the best play? Stay on the sidelines. INO stock is too overvalued to go long. But, unpredictability makes it a weak short candidate. Staying on the fence may be the best move.
